中访网数据 石药创新制药股份有限公司于2025年10月16日召开2025年第二次临时股东大会，审议通过了多项重要议案。核心决议包括批准公司首次公开发行境外上市股份(H股)并在香港联合交易所主板上市的相关方案、授权及配套制度修订。具体方案涵盖上市地点、发行规模、定价方式等细节，并确定了H股发行前的滚存利润分配方案。同时，大会通过了现金收购控股子公司石药集团巨石生物制药有限公司部分少数股权暨关联交易的议案。此外，会议还修订了《公司章程》等内部治理制度，并审议通过了增选周宏为公司独立非执行董事、投保董监高责任险等议案。所有议案均获得有效表决通过，其中涉及H股发行及章程修订等关键议案均获出席股东大会有效表决权股份总数的三分之二以上同意。此次决议标志着石药创新制药在资本国际化及内部治理优化方面迈出重要一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.